Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 251 - 300 av 380 resultater
Tid
Selskap
Tittel
Sektor
Kategori
06 Jan 2023
18:00 CET
IPSEN
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
20103015 Pharmaceuticals
Corporate life
06 Jan 2023
18:00 CET
IPSEN
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
20103015 Pharmaceuticals
Corporate life
06 Jan 2023
18:00 CET
IPSEN
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Corporate life
06 Jan 2023
18:00 CET
IPSEN
Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF
20103015 Pharmaceuticals
Corporate life
23 Dec 2022
23:00 CET
IPSEN
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
20103015 Pharmaceuticals
Products and services
23 Dec 2022
23:00 CET
IPSEN
Ipsen reçoit une lettre de réponse complète pour le palovarotène, traitement expérimental de la fibrodysplasie ossifiante progressive
20103015 Pharmaceuticals
Products and services
09 Dec 2022
18:00 CET
IPSEN
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
20103015 Pharmaceuticals
Corporate life
09 Dec 2022
18:00 CET
IPSEN
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Corporate life
08 Dec 2022
22:05 CET
IPSEN
Ipsen communique le résultat de l’essai de Phase III CONTACT-01 évaluant cabozantinib associé avec atézolizumab chez les patients déjà traités par immunothérapie et chimiothérapie atteints d’un cancer du poumon non à petites cellules métastatique
20103015 Pharmaceuticals
Products and services
08 Dec 2022
22:05 CET
IPSEN
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
20103015 Pharmaceuticals
Products and services
10 Nov 2022
18:00 CET
IPSEN
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
10 Nov 2022
18:00 CET
IPSEN
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
20103015 Pharmaceuticals
Share history
09 Nov 2022
07:01 CET
IPSEN
Onivyde® démontre une amélioration statistiquement significative de la survie globale chez les patients atteints d’un adénocarcinome canalaire pancréatique métastatique non précédemment traités
20103015 Pharmaceuticals
Products and services
09 Nov 2022
07:01 CET
IPSEN
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
20103015 Pharmaceuticals
Products and services
27 Oct 2022
06:57 CEST
IPSEN
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
20103015 Pharmaceuticals
Sales
27 Oct 2022
06:57 CEST
IPSEN
Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022
20103015 Pharmaceuticals
Sales
25 Oct 2022
16:20 CEST
IPSEN
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
20103015 Pharmaceuticals
Other subject
25 Oct 2022
16:20 CEST
IPSEN
Déclaration d’Ipsen concernant la mise à jour du calendrier de réunion du Comité consultatif de la FDA sur le palovarotène
20103015 Pharmaceuticals
Other subject
10 Oct 2022
18:00 CEST
IPSEN
Ipsen: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Corporate life
10 Oct 2022
18:00 CEST
IPSEN
Ipsen: Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Corporate life
09 Sep 2022
18:00 CEST
IPSEN
Ipsen: Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Legal
09 Sep 2022
18:00 CEST
IPSEN
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Legal
06 Sep 2022
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 29/08/2022 To 02/09/2022
20103015 Pharmaceuticals
Legal
06 Sep 2022
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 29 Août au 02 Septembre 2022
20103015 Pharmaceuticals
Legal
30 Aug 2022
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 22 au 26 Août 2022
20103015 Pharmaceuticals
Legal
30 Aug 2022
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 22/08/2022 To 26/08/2022
20103015 Pharmaceuticals
Legal
23 Aug 2022
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 15 au 19 Août 2022
20103015 Pharmaceuticals
Legal
23 Aug 2022
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 15/08/2022 To 19/08/2022
20103015 Pharmaceuticals
Legal
12 Aug 2022
17:35 CEST
IPSEN
Ipsen finalise l’acquisition d’Epizyme et étend son portefeuille en Oncologie
20103015 Pharmaceuticals
Mergers, Acquiqitions, Transferts
12 Aug 2022
17:35 CEST
IPSEN
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
20103015 Pharmaceuticals
Mergers, Acquiqitions, Transferts
10 Aug 2022
18:00 CEST
IPSEN
Ipsen : Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
20103015 Pharmaceuticals
Other subject
10 Aug 2022
18:00 CEST
IPSEN
Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Other subject
09 Aug 2022
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares between 01/08/2022 to 05/08/2022
20103015 Pharmaceuticals
Legal
09 Aug 2022
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 01 au 05 Août 2022
20103015 Pharmaceuticals
Legal
05 Aug 2022
07:00 CEST
IPSEN
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
20103015 Pharmaceuticals
Mergers, Acquiqitions, Transferts
05 Aug 2022
07:00 CEST
IPSEN
Ipsen annonce l’extension de son offre publique d’achat des actions d’Epizyme, Inc. au 11 août 2022
20103015 Pharmaceuticals
Mergers, Acquiqitions, Transferts
03 Aug 2022
07:00 CEST
IPSEN
Ipsen annonce les résultats de l’étude de Phase III RESILIENT évaluant Onivyde® comme monothérapie de deuxième ligne dans le cancer du poumon à petites cellules
20103015 Pharmaceuticals
Products and services
03 Aug 2022
07:00 CEST
IPSEN
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
20103015 Pharmaceuticals
Products and services
02 Aug 2022
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 25/07/2022 To 29/07/2022
20103015 Pharmaceuticals
Legal
02 Aug 2022
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 25 au 29 Juillet 2022
20103015 Pharmaceuticals
Legal
01 Aug 2022
07:00 CEST
IPSEN
Ipsen et Marengo Therapeutics annoncent la conclusion d’un partenariat stratégique afin de développer deux traitements candidats de précision en immuno-oncologie en phase clinique à partir de la plateforme STAR de Marengo
20103015 Pharmaceuticals
Alliances and agreements
01 Aug 2022
07:00 CEST
IPSEN
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
20103015 Pharmaceuticals
Alliances and agreements
28 Jul 2022
06:57 CEST
IPSEN
Ipsen publie de solides résultats pour le premier semestre et revoit à la hausse ses objectifs pour l’exercice en cours
20103015 Pharmaceuticals
Sales
28 Jul 2022
06:57 CEST
IPSEN
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
20103015 Pharmaceuticals
Sales
26 Jul 2022
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 18 au 22 Juillet 2022
20103015 Pharmaceuticals
Legal
26 Jul 2022
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 18/07/2022 to 22/07/2022
20103015 Pharmaceuticals
Legal
19 Jul 2022
18:00 CEST
IPSEN
Ipsen: Disclosure Transaction in Own Shares Between 11/07/2022 to 15/07/2022
20103015 Pharmaceuticals
Legal
19 Jul 2022
18:00 CEST
IPSEN
Ipsen : Déclaration des transactions sur actions propres réalisées du 11 au 15 Juillet 2022
20103015 Pharmaceuticals
Legal
06 Jul 2022
18:00 CEST
IPSEN
Half-Year Statement of IPSEN Liquidity Agreement with NATIXIS ODDO BHF
20103015 Pharmaceuticals
Share history
06 Jul 2022
18:00 CEST
IPSEN
Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
20103015 Pharmaceuticals
Share history
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
5
6
7
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva